Howard Grossberg

906 total citations
12 papers, 743 citations indexed

About

Howard Grossberg is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Howard Grossberg has authored 12 papers receiving a total of 743 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Molecular Biology and 2 papers in Genetics. Recurrent topics in Howard Grossberg's work include Cancer therapeutics and mechanisms (4 papers), HER2/EGFR in Cancer Research (3 papers) and Estrogen and related hormone effects (2 papers). Howard Grossberg is often cited by papers focused on Cancer therapeutics and mechanisms (4 papers), HER2/EGFR in Cancer Research (3 papers) and Estrogen and related hormone effects (2 papers). Howard Grossberg collaborates with scholars based in United States, Switzerland and India. Howard Grossberg's co-authors include Y A Teramoto, L. Demers, Kim Leitzel, A. Lipton, V. M. Chinchilli, H Harvey, Kerstin Konrad, Laurence M. Demers, Harold A. Harvey and Richard J. Santen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The American Journal of Medicine.

In The Last Decade

Howard Grossberg

12 papers receiving 716 citations

Peers

Howard Grossberg

ONCOL

MB

GENET

RNMI

CR

Lavina Bharwani Singapore

B. Lisboa Germany

S. Johnston United Kingdom

A McKinna United Kingdom

J.-M. Nabholtz Canada

R.K. Gregory United Kingdom

D. R. Budman United States

Shane K. Green Canada

Svend A. Engelholm Denmark

Katherine Ory France

Lavina Bharwani Singapore

Howard Grossberg

491 ×1.1

ONCOL

356 ×1.3

MB

289 ×1.4

GENET

120 ×0.7

RNMI

149 ×1.2

CR

Citations per year, relative to Howard Grossberg Howard Grossberg (= 1×) peers Lavina Bharwani

Countries citing papers authored by Howard Grossberg

Since Specialization

Citations

This map shows the geographic impact of Howard Grossberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard Grossberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard Grossberg more than expected).

Fields of papers citing papers by Howard Grossberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Howard Grossberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard Grossberg. The network helps show where Howard Grossberg may publish in the future.

Co-authorship network of co-authors of Howard Grossberg

This figure shows the co-authorship network connecting the top 25 collaborators of Howard Grossberg. A scholar is included among the top collaborators of Howard Grossberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Howard Grossberg. Howard Grossberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Spitzer, Thomas R., Steven L. McAfee, Bimalangshu R. Dey, et al.. (2003). Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation. 75(10). 1748–1751. 92 indexed citations

2.

Leitzel, Kim, et al.. (1996). Serial serum c-erbB-2 levels in patients with breast carcinoma. Cancer. 78(2). 267–272. 44 indexed citations

3.

Leitzel, Kim, et al.. (1996). Serial serum c‐erbB‐2 levels in patients with breast carcinoma. Cancer. 78(2). 267–272. 1 indexed citations

4.

Leitzel, Kim, Y A Teramoto, Kerstin Konrad, et al.. (1995). Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.. Journal of Clinical Oncology. 13(5). 1129–1135. 247 indexed citations

5.

Demers, Laurence M., et al.. (1995). Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer. 75(8). 2132–2138. 93 indexed citations

6.

Demers, Laurence M., et al.. (1993). The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. The Journal of Steroid Biochemistry and Molecular Biology. 44(4-6). 687–691. 70 indexed citations

7.

Berek, JS, et al.. (1992). A phase I–II trial of intraperitoncal cisplatin and a‐interferon in patients with persistent epithelial ovarian cancer. International Journal of Gynecology & Obstetrics. 37(4). 330–330. 1 indexed citations

8.

Berek, Jonathan S., et al.. (1990). A phase I–II trial of intraperitoneal cisplatin and α-lnterferon in patients with persistent epithelial ovarian cancer. Gynecologic Oncology. 40(3). 237–243. 32 indexed citations

9.

Grossberg, Howard. (1990). Successful use of granulocyte-macrophage colony-stimulating factor in patients with acute lymphocytic leukemia. The American Journal of Medicine. 89(3). 384–386. 4 indexed citations

10.

Walsh, Christine, J Wernz, H. S. Hochster, et al.. (1989). Phase I study of the combination of alpha-2 interferon and cisplatinum.. PubMed. 8(1). 11–5. 13 indexed citations

11.

Potmĕsil, M, Y H Hsiang, Leroy F. Liu, et al.. (1988). Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II.. PubMed. 48(12). 3537–43. 143 indexed citations

12.

Grossberg, Howard, et al.. (1987). Treatment of advanced refractory lymphoma with teniposide and lomustine.. PubMed. 71(2). 215–6. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact